Electrochemical Behavior of Vindesine at Nanoflower CuS/Graphene Modified Glassy Carbon Electrode
摘 要
通过改进的Hummers法和溶剂热法分别制备了石墨烯和硫化铜纳米花。采用滴涂法进一步依次将石墨烯和硫化铜纳米花修饰于玻碳电极,制备了硫化铜纳米花/石墨烯修饰玻碳电极(Nanoflower CuS/GR/GCE)。利用循环伏安法和差分脉冲伏安法等研究了长春地辛在该修饰电极的电化学行为。结果表明:长春地辛的浓度在1.0×10-8~1.0×10-7mol·L-1,1.0×10-7~1.1×10-5mol·L-1及1.1×10-5~1.0×10-4mol·L-1内与其对应的峰电流的减小量呈线性关系,检出限(3S/N)为4.9×10-9mol·L-1。对1.0×10-6mol·L-1长春地辛标准溶液连续测定5次,测定值的相对标准偏差为1.2%。方法用于长春地辛药品样品的分析,加标回收率在97.1%~103%之间。
Abstract
Graphene and CuS nanoflower were prepared respectively by modified Hummers method and solvothermal method. And then nanoflower CuS and graphen were coated by dropping successively onto the surface of glassy carbon electrode, to prepare the nanoflower CuS-graphene modified GCE (abbrev. as nanoflower CuS/GF/GCE). The electrochemical behavior of vindesine at this modified electrode was studied by cyclic voltametry and different pulse voltametry. It was found that linear relationship between the magnitude of decrease of oxidation peak current and concentration of vindesine was obtained in the ranges of 1.0×10-8 to 1.0×10-7mol·L-1, 1.0×10-7 to 1.1×10-5mol·L-1 and 1.1×10-5 to 1.0×10-4mol·L-1, with detection limit (3S/N) of 4.9×10-9mol·L-1. Precision of the method was tested at the concentration of 1.0×10-6mol·L-1 vindesine standard solution for 5 determinations, value of RSD found was 1.2%. The proposed method was applied to the analysis of drug samples of vindesine, giving values of recovery in the range of 97.1%-103%.
中图分类号 O657.1 DOI 10.11973/lhjy-hx201705006
所属栏目 工作简报
基金项目 山西省自然科学基金(20001057)
收稿日期 2016/7/15
修改稿日期
网络出版日期
作者单位点击查看
备注高宝平(1976-),男,山西临县人,讲师,硕士,研究方向为电分析化学
引用该论文: GAO Baoping,GUO Mandong,WU Wuai. Electrochemical Behavior of Vindesine at Nanoflower CuS/Graphene Modified Glassy Carbon Electrode[J]. Physical Testing and Chemical Analysis part B:Chemical Analysis, 2017, 53(5): 522~526
高宝平,郭满栋,武五爱. 长春地辛在硫化铜纳米花/石墨烯修饰玻碳电极上的电化学行为[J]. 理化检验-化学分册, 2017, 53(5): 522~526
共有人对该论文发表了看法,其中:
人认为该论文很差
人认为该论文较差
人认为该论文一般
人认为该论文较好
人认为该论文很好
参考文献
【1】祖元刚,付玉杰,罗猛,等.长春碱的抗癌活性及其降低毒性的结构修饰[J].化学通报(网络版), 2004,67(w027):1-5.
【2】丁亚芳,包永明,安利佳.长春碱类抗肿瘤药物的研究进展[J].中国医药工业杂志, 2005,36(7):424-428.
【3】王金万,张和平,张燕.西艾克治疗恶性肿瘤的临床Ⅲ期试用报告[J].中华肿瘤杂志, 1996,8(4):285-288.
【4】ZHOU Xiao-jian, RANMANI R. Preclinical pharmacology ofvinca alkaloids[J]. Drugs, 1992,44(4):1-16.
【5】SANTO A, GENESTRETI G, TERZI A, et al. Gemcitabine (GEM) and Vindesine (VDS) in advanced non-small cell lung cancer (NSCLC):A phase Ⅱstudy in elderly or poor performance status patients[J]. Lung Cancer, 2006,53(3):355-360.
【6】NISHIMURA K Y, TSUJINO M, SATOUCHI M. Phase Ⅲstudy of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplastin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (CTR) for patients (pts) with unresectable stage Ⅲ non-small cell lung cancer; special reference on delivry of TRT[J]. European Journal of Cancer Supplement, 2009,7(2):534-535.
【7】RHOMBERG W, WINK A, POKRAJAC B, et al. Treatment of vascular soft tissue sarcomas with razoxane, vindesine, and radiation[J]. Journal of Radiation Oncology*Biology*Physics, 2009,74(1):187-191.
【8】ZHU R H, LI H D, CAI H L, et al. Validated HILIC-MS/MS assay for determination of vindesine in human plasma:application to a population pharmacokinetic study[J]. Journal of Pharmaceutical and Biomedical Analysis, 2014(96):31-36.
【9】陈钰,黄宗玉.硫酸长春地辛及其注射剂有关物质检查方法的改进[J].色谱, 1999,17(1):85-86.
【10】李杨,杨季冬.长春地辛-赤鲜红体系的吸收、荧光和共振散射光谱的研究及其分析应用[J].化学试剂, 2009,31(12):1000-1004.
【11】刘计敏,郑崇涛,李玲,等.新型抗癌药物长春地辛的电化学研究[J].分析科学学报, 2016,32(3):353-356.
【12】洪菲,周立群,黄莹,等.改进hummers法化学合成石墨烯及其表征[J].化学与生物工程, 2012,29(5):31-33.
【2】丁亚芳,包永明,安利佳.长春碱类抗肿瘤药物的研究进展[J].中国医药工业杂志, 2005,36(7):424-428.
【3】王金万,张和平,张燕.西艾克治疗恶性肿瘤的临床Ⅲ期试用报告[J].中华肿瘤杂志, 1996,8(4):285-288.
【4】ZHOU Xiao-jian, RANMANI R. Preclinical pharmacology ofvinca alkaloids[J]. Drugs, 1992,44(4):1-16.
【5】SANTO A, GENESTRETI G, TERZI A, et al. Gemcitabine (GEM) and Vindesine (VDS) in advanced non-small cell lung cancer (NSCLC):A phase Ⅱstudy in elderly or poor performance status patients[J]. Lung Cancer, 2006,53(3):355-360.
【6】NISHIMURA K Y, TSUJINO M, SATOUCHI M. Phase Ⅲstudy of mitomycin/vindesine/cisplatin (MVP) versus weekly irinotecan/carboplastin (IC) or weekly paclitaxel/carboplatin (PC) with concurrent thoracic radiotherapy (CTR) for patients (pts) with unresectable stage Ⅲ non-small cell lung cancer; special reference on delivry of TRT[J]. European Journal of Cancer Supplement, 2009,7(2):534-535.
【7】RHOMBERG W, WINK A, POKRAJAC B, et al. Treatment of vascular soft tissue sarcomas with razoxane, vindesine, and radiation[J]. Journal of Radiation Oncology*Biology*Physics, 2009,74(1):187-191.
【8】ZHU R H, LI H D, CAI H L, et al. Validated HILIC-MS/MS assay for determination of vindesine in human plasma:application to a population pharmacokinetic study[J]. Journal of Pharmaceutical and Biomedical Analysis, 2014(96):31-36.
【9】陈钰,黄宗玉.硫酸长春地辛及其注射剂有关物质检查方法的改进[J].色谱, 1999,17(1):85-86.
【10】李杨,杨季冬.长春地辛-赤鲜红体系的吸收、荧光和共振散射光谱的研究及其分析应用[J].化学试剂, 2009,31(12):1000-1004.
【11】刘计敏,郑崇涛,李玲,等.新型抗癌药物长春地辛的电化学研究[J].分析科学学报, 2016,32(3):353-356.
【12】洪菲,周立群,黄莹,等.改进hummers法化学合成石墨烯及其表征[J].化学与生物工程, 2012,29(5):31-33.
相关信息